Navigation Links
SyntheMed Receives Frost & Sullivan Health Innovation Award Nomination
Date:6/23/2009

ISELIN, N.J., June 23 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion products, announced today that the company was recently nominated for the prestigious Frost & Sullivan Health Innovation Award in pediatrics. The company is among three nominated in this category by Frost & Sullivan medical device analysts in recognition of the development of REPEL-CV(TM) Bioresorbable Adhesion Barrier. The award is presented annually to a medical device company demonstrating innovation in new product development.

About REPEL-CV

REPEL-CV is a bioresorbable adhesion barrier film designed to be placed over the surface of the heart at the conclusion of an open-heart surgical procedure to reduce the extent and severity of adhesions (scar tissue) that form between the surface of the heart and opposing tissue surfaces following the surgical procedure. REPEL-CV is FDA approved for use in pediatric cardiac surgery patients and is marketed in the United States through a direct sales force. It also has CE Mark approval for use in all cardiac surgery patients and is marketed in the European Union and certain other international countries through a network of independent distributors.

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion products. The company is primarily focused on the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technology.

About Frost and Sullivan

Frost & Sullivan, the Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. For nearly 50 years Frost & Sullivan has partnered with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

Statements in this Press Release that are not statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the company's efforts to obtain and maintain FDA and other required regulatory approvals; (ii) potential inability to secure funding as and when needed to support the company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the company's Annual Report on Form 10-KSB for the year ended December 31, 2008 for a description of these, as well as other, risks and uncertainties.


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
2. SyntheMed to Present at the Acumen BioFin Conference
3. SyntheMed Files Universal Shelf Registration
4. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
5. SyntheMed To Present at the AdvaMed 2008 MedTech Conference
6. SyntheMed Completes $4.0 Million Equity Placement
7. SyntheMed Announces New Management Appointments
8. SyntheMed Announces FDA Clearance of SinusShield(TM)
9. FDA Approves SyntheMeds REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery
10. SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R)
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... Columbia , May 19, 2016  AdvancedFlow ... Innovations Inc. (AGI), based out of ... Greenlane Biogas Ltd. to its existing portfolio of ... manufacturing agreement. AFS along with its sister companies ... is a vertically integrated industrial group that specializes ...
(Date:5/18/2016)... ... May 18, 2016 , ... Tech Coast Angels ... Villalobos Award to Cognition Therapeutics at the annual ACA Summit last week in Philadelphia. ... financed by one of ACA’s member angel groups. It is the highest honor available ...
(Date:5/18/2016)... IN (PRWEB) , ... May 18, 2016 , ... The ... and is now celebrating its dream of reaching a total of $1 million in ... scholarships awarded to 10 high school graduates from across the nation has helped bring ...
(Date:5/17/2016)... (PRWEB) , ... May 17, 2016 , ... ... Deliver Global Conference that they will collaborate to bring a feeding cup to ... School of Dentistry, and the Craniofacial Center at Seattle Children’s Hospital, thereby ensuring ...
Breaking Biology Technology:
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ) - ... ( http://www.apimages.com ) - Germany . The ... refugee identity cards. DERMALOG will be unveiling this device, and a ... next week.   --> Germany . ... new refugee identity cards. DERMALOG will be unveiling this device, and ...
(Date:3/10/2016)... , March 10, 2016   Unisys Corporation (NYSE: ... Border Protection (CBP) is testing its biometric identity solution ... Diego to help identify certain non-U.S. citizens leaving ... The test, designed to help determine the efficiency and accuracy ... in February and will run until May 2016. --> ...
(Date:3/9/2016)... Fla. , March 9, 2016  Crossmatch ... authentication and enrollment solutions, today announced the addition ... ® Altus multi-factor authentication platform. New ... InfoSec managers to step-up security where it,s needed ... Washington, DC . --> ...
Breaking Biology News(10 mins):